Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based Advisor operating in the Medical space. If you think a Advisor is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
David Rust
Co-Founder & Advisor of Lively
David is a seasoned operator who helped scale Lyft from 25 to 1,600 employees and an $11B+ valuation. He launched Lyft’s first markets across the US and translated these learnings into the company’s national expansion playbook. David then went on to build and lead Lyft’s internal strategy team, reporting to Lyft’s COO. This team was responsible for leading high-priority strategic initiatives, from Lyft’s partnership with General Motors to its first self-driving car implementations. Prior to Lyft, David led market expansion and local marketing for one of the early pioneers in the car sharing industry, Wheelz, which was acquired by RelayRides (not Turo). David graduated from Stanford University with a degree in Environmental Engineering and was named as a member of the Forbes 30 Under 30 class of 2017.
Follow David Rust:
About Lively: Lively’s mission is to democratize, simplify and de-stigmatize the adoption and use of technically advanced hearing aids.
Beverley Kane
Member of the Medical Advisory Board of Healthline Media
Kane is a medical informatics specialist who received her medical degree from the University of California San Francisco. She completed a Family Practice Residency at San Francisco General Hospital, where she co-created the Department of Medicine’s Alternative Therapies Unit, one of the first programs of its kind in a major US medical center. She became board certified in Family Practice and completed fellowships in Obstetrics and Gynecology and in Sports Medicine. She worked in the private practice of sports medicine in San Francisco, where she was medical director of the San Francisco Marathon; in multiple risk factor intervention at the Stanford Center for Research in Disease Prevention; as the physician at Apple Computer for nearly 10 years; as chief medical officer of Philips Medical Systems’ EMR division; and as the consumer-professional portals liaison at WebMD. Passionate about the provider-patient relationship, Kane chaired the American Medical Informatics Association’s Internet Working Group and co-wrote AMIA’s Guidelines for the Clinical Use of Electronic Mail With Patients. She now consults at Healthline and teaches, with her equine partners, Medicine and Horses, a doctor-patient communications course at Stanford Medical School.
Follow Beverley Kane:
About : Healthline Media is the 2nd largest and fastest growing consumer health publisher in the world, reaching 85 million people a month.
Abbie Barbir
Senior Security Advisor of Aetna
Follow Abbie Barbir:
About : Aetna a diversified health care benefits company, provides individuals and many others with innovative benefits, products, and services.
Rupinder Singh
Sr Application Software Delivery Advisor of Aetna
Follow Rupinder Singh:
About : Aetna a diversified health care benefits company, provides individuals and many others with innovative benefits, products, and services.
Lien Suandy
Senior Application Software Delivery Advisor of Aetna
Senior Application Software Delivery Advisor at Aetna.
Follow Lien Suandy:
About : Aetna a diversified health care benefits company, provides individuals and many others with innovative benefits, products, and services.
Lien Suandy
Senior Application Software Delivery Advisor of Aetna
Senior Application Software Delivery Advisor at Aetna.
Follow Lien Suandy:
About : Aetna a diversified health care benefits company, provides individuals and many others with innovative benefits, products, and services.
Ronald Greeno
Board Advisor of Honor
Ronald Greeno, MD is the Chief Strategy Officer for IPC Healthcare, Inc. and was the Co-Founder of Cogent Healthcare Inc. where he served most recently as Executive Vice President of Strategy & Innovation. Prior to that, he was the Chief Medical Officer of Cogent Healthcare Inc. for 17 years, responsible for developing and managing Cogent’s national network of hospitalist physicians and for the development of the medical management approach. Considered a pioneer in Hospital Medicine, Ronald Greeno is a nationally recognized expert on hospitalist programs and their clinical and administrative management.
Follow Ronald Greeno:
About : Honor is a senior care network and technology platform that offers personalized care to improve the in-home care experience.
Charles Sawyers
Member of the Scientific Advisory Board of Blueprint Medicines
Charles Sawyers has been a member of the Board of Directors since 2013. He qualifies as an independent Non-Executive Director. He is a member of the Research & Development Committee and the Governance, Nomination and Corporate Responsibilities Committee. In the United States Sawyers is chair of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center, professor of medicine and of cell and developmental biology at the Weill Cornell Graduate School of Medical Sciences, and an investigator at the Howard Hughes Medical Institute. He serves on US President Barack Obama’s National Cancer Advisory Board and is past president of the American Association of Cancer Research and former president of the American Society for Clinical Investigation. He also is a member of the US National Academy of Sciences and Institute of Medicine. Sawyers received his M.D. from the Johns Hopkins School of Medicine in the United States, and worked at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, for nearly 18 years before joining Memorial SloanKettering in 2006. An internationally acclaimed cancer researcher, he co-developed the Novartis cancer drug Gleevec/Glivec, and has received numerous honors and awards, including the LaskerDeBakey Clinical Medical Research Award in 2009. Sawyers is a member of the Scientific Advisory Board of Agios Pharmaceuticals, Inc. in the United States.
Follow Charles Sawyers:
About ORIC Pharmaceuticals, The Howard Hughes Medical Institute, Weill Cornell Graduate School of Medical Sciences: Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.
William Hahn
Member of the Scientific Advisory Board of Blueprint Medicines
William Hahn is a Chief Operating Officer at the Dana-Farber Cancer Institute. Also at Dana-Faber, he co-directs the Center for Cancer Genome Discovery and serves as the Chief of the Division of Molecular and Cellular Oncology as well as Chair of the Executive Committee for Research. He is an Institute Member of the Broad Institute of MIT and Harvard. Hahn has made numerous seminal discoveries that have informed our current molecular understanding of cancer and which have defined new conceptual paradigms and formed the foundation of new translational studies.
Follow William Hahn:
About Broad Institute, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Solasta Ventures: Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.
Francesco Izzo
Surgeon Advisory Board of Domain Surgical
Dr. Francesco Izzo received his medical degree from the University of Naples, Federico II Medical School, Italy. He completed a general surgery residency at the University of Naples, Italy and then completed a fellowship in Surgical Oncology at the University of Texas Anderson Cancer Center. Dr. Izzo has been on the faculty in the Department of Surgical Oncology at the National Cancer Institute of Naples, Italy since completing his fellowship. He is now Full Professor of Surgery, Director and Coordinator of the Abdominal and Hepatobiliary Surgical Oncology Division and Chief of Liver Tumor Study Group at the National Cancer Institute of Naples, Italy. Dr. Izzo’s clinical practice and research focuses on surgical oncology new treatments particularly for patients with Hepatobiliary and pancreatic tumors. Dr. Izzo has been a pioneer in designing new treatments for patients with liver tumors, including radiofrequency ablation, improved techniques for surgical removal of liver cancers, and several types of direct tumor injection therapy. Dr Izzo is principal investigator on a number of National and International protocols for the basic science and clinical treatment on primary and metastatic hepatobiliary cancers Dr. Izzo is the author or co-author of over 220 publications, 18 book chapters, many dealing with the treatment of patients with hepatocellular cancer, gallbladder cancer, bile duct cancer, pancreatic cancer or metastases from a number of different tumor types.
Follow Francesco Izzo:
About : Domain Surgical creates energy-based surgical products for precise soft tissue cutting and coagulation.
Robert Glasgow
Surgeon Advisory Board of Domain Surgical
Dr. Robert E. Glasgow is currently an Associate Professor (Clinician Scholar) at the University of Utah School of Medicine, Director of Minimally Invasive Surgery and Section Chief of Gastrointestinal and General Surgery for the Division of General Surgery, and Vice Chairman of Clinical Operations and Quality for the Department of Surgery at the University of Utah. After graduating with a Bachelor of Science from Stanford University and Doctor of Medicine from the University of California, San Francisco, Dr. Glasgow completed a General Surgery Residency and Research Fellowship in Gastrointestinal Surgery at the University of California, San Francisco then a Fellowship in Advanced Minimally Invasive and Gastrointestinal Surgery at Legacy Health System in Portland, Oregon. Dr. Glasgow’s clinical and research focus is in the area of gastrointestinal surgery with a special emphasis on minimally invasive techniques in the management of gastroesophageal and hepatopancreatobiliary disorders. Dr. Glasgow specializes in the treatment of benign and malignant disorders of the esophagus, stomach, intestines, liver, gallbladder, pancreas and biliary tree. He is also an expert in the minimally invasive treatment of hernia disease, including abdominal wall and groin hernias as well as hiatal hernias. As his research and administrative interests are in the area of optimization of surgical quality and outcomes, Dr. Glasgow directs the Department of Surgery participation in the American College of Surgeons’ National Surgical Quality Improvement Program. In this role, he helps to oversee quality improvment projects within the Department of Surgery with the goal of maintaining the University of Utah at the highest level of surgical care in the country.
Follow Robert Glasgow:
About University of Utah School of Medicine: Domain Surgical creates energy-based surgical products for precise soft tissue cutting and coagulation.
Timothy Kriewall
Corporate Advisory Board of Domain Surgical
Dr. Kriewall is presently a Program Director at the Kern Family Foundation, a non-profit organization committed to driving entrepreneurial education in engineering pedagogy at private universities across the United States. He is also President Emeritus of Wisconsin Lutheran College located in Milwaukee, Wisconsin. From 2000 to 2003, Dr. Kriewall was Vice President of Research and Development at Medtronic Xomed, where his teams developed surgical tools for ear-nose-throat (ENT) surgery. Earlier in his career he was Director of Research and Development at Medtronic Perfusion Systems, and Technical Manager at 3M Cardiovascular Systems, where he was responsible for the development of cardiopulmonary bypass systems. While at 3M, he was the technical lead for the first-ever cochlear implant to receive FDA approval in 1984. Dr. Kriewall holds Bachelor’s and Master’s degrees in electrical and computer engineering from the University of Michigan and Stanford University, respectively, and a Ph.D. in biomedical engineering from the University of Michigan where he served on their faculty for eight years before entering industry in 1981. He left Michigan as an Associate Professor of Obstetrics and Gynecology where he conducted research in the field of perinatal medicine. Dr. Kriewall is a Fellow of the American Institute of Engineering in Medicine and Biology. He has authored 19 publications in scientific journals, presented at numerous national and international meetings, written chapters in medical text books, and he is a co-inventor named on five patents.
Follow Timothy Kriewall:
About : Domain Surgical creates energy-based surgical products for precise soft tissue cutting and coagulation.
Frank Shannon
Corporate Advisory Board of Domain Surgical
Dr. Shannon is a cardiovascular surgeon with William Beaumont Hospital in Royal Oak, Michigan. Dr. Shannon has authored numerous publications in cardiovascular and general surgery, and is a reviewer for the Annals of Thoracic Surgery. Dr. Shannon is a well-known surgical valve design innovator, with particular expertise in mitral and tricuspid valve systems, percutaneous/minimally accessible mitral annular remodeling devices, aortic valves, and minimally invasive devices used in atrial ablation procedures. Dr. Shannon sits on the scientific advisory board of Micardia, a BioStar Ventures portfolio company, and is a consultant to Medtronic, Datascope, and Pequot Capital Management.
Follow Frank Shannon:
About Datascope Corp, Medtronic, William Beaumont Hospital: Domain Surgical creates energy-based surgical products for precise soft tissue cutting and coagulation.
Jim Krieg
Corporate Advisory Board of Domain Surgical
Dr. Krieg is an Associate Professor of Orthopaedic Surgery at the University of Washington and Harborview Medical Center in Seattle, Washington. He is a board certified surgeon whose practice focuses on orthopedic trauma, including care of complex fractures and management of multiply injured patients. An active researcher and educator, he teaches nationally and internationally. He currently serves on the North American Musculoskeletal Trauma Education Committee of the Arbeitsgemeinshaft fur Osteosyntesefragen (AO). As an innovator, he has seen two of his ideas for medical devices successfully developed and brought to market. He is a frequent industry collaborator and invited speaker.
Follow Jim Krieg:
About University of Washington: Domain Surgical creates energy-based surgical products for precise soft tissue cutting and coagulation.
Frank Shannon
Corporate Advisory Board of Domain Surgical
Dr. Shannon is a cardiovascular surgeon with William Beaumont Hospital in Royal Oak, Michigan. Dr. Shannon has authored numerous publications in cardiovascular and general surgery, and is a reviewer for the Annals of Thoracic Surgery. Dr. Shannon is a well-known surgical valve design innovator, with particular expertise in mitral and tricuspid valve systems, percutaneous/minimally accessible mitral annular remodeling devices, aortic valves, and minimally invasive devices used in atrial ablation procedures. Dr. Shannon sits on the scientific advisory board of Micardia, a BioStar Ventures portfolio company, and is a consultant to Medtronic, Datascope, and Pequot Capital Management.
Follow Frank Shannon:
About Datascope Corp, Medtronic, William Beaumont Hospital: Domain Surgical creates energy-based surgical products for precise soft tissue cutting and coagulation.
Jim Krieg
Corporate Advisory Board of Domain Surgical
Dr. Krieg is an Associate Professor of Orthopaedic Surgery at the University of Washington and Harborview Medical Center in Seattle, Washington. He is a board certified surgeon whose practice focuses on orthopedic trauma, including care of complex fractures and management of multiply injured patients. An active researcher and educator, he teaches nationally and internationally. He currently serves on the North American Musculoskeletal Trauma Education Committee of the Arbeitsgemeinshaft fur Osteosyntesefragen (AO). As an innovator, he has seen two of his ideas for medical devices successfully developed and brought to market. He is a frequent industry collaborator and invited speaker.
Follow Jim Krieg:
About University of Washington: Domain Surgical creates energy-based surgical products for precise soft tissue cutting and coagulation.
David Thomas
Corporate Advisory Board of Domain Surgical
Dr. Thomas is a practicing plastic surgeon in Salt Lake City, Utah. He attended the University of Utah for undergraduate and medical school, graduating in 1974. He completed his residency training in general surgery and plastic surgery at UCLA Medical Center, and completed an additional fellowship in craniofacial surgery under the tutelage of Dr. Henry Kawamoto, one of the world’s leading experts in this field, at UCLA. From 1990 to 1993, in addition to maintaining his private practice, he became a full time member of the faculty of the University of Utah School of Medicine as Associate Professor of Surgery in Plastic Surgery. Dr. Thomas has served on the Board of Directors of Interplast, Inc., a non-profit organization providing reconstructive surgery to patients in underdeveloped countries, and has volunteered services on several trips to South and Central America, Asia, and Africa.He is the past President of the Utah State Plastic Surgery Society and past Chairman of the Division of Plastic Surgery at LDS Hospital and Primary Children’s Medical Center. Dr. Thomas is Board Certified by the American Board of Plastic Surgery, and is a member of the American Society of Plastic Surgeons, American Society for Aesthetic Plastic Surgery, American Society of Maxillofacial Surgery, Utah State Plastic Surgery Society, Salt Lake Surgical Society, and he is a Fellow of the American College of Surgeons.
Follow David Thomas:
About : Domain Surgical creates energy-based surgical products for precise soft tissue cutting and coagulation.
Francis Wapner
Corporate Advisory Board of Domain Surgical
Dr. Wapner is a practicing ophthalmologist in Salt Lake City, Utah. He completed his undergraduate studies at the University of Pennsylvania where he graduated Magna Cum Laude. He continued his studies at Columbia University where he received his doctorate in medicine. Dr. Wapner served his internship at the University of Utah/LDS Hospital in Salt Lake City. Following his internship he went on to become Chief Resident at the Edward S. Harkness Eye Institute at Columbia University.Dr. Wapner serves as a clinical instructor in Ophthalmology at the University of Utah. He is the Medical Director at the Physicians Surgery Center, as well as the Chairman of the Department of Ophthalmology at St. Marks Hospital. Dr. Wapner is board certified by the American Academy of Ophthalmology. He is a Fellow of the American College of Surgeons, as well as a member of the American Academy of Ophthalmology, American Board of Ophthalmology, and American Society of Cataract and Refractive Surgeons.
Follow Francis Wapner:
About Physicians Surgery Center, University of Utah: Domain Surgical creates energy-based surgical products for precise soft tissue cutting and coagulation.
Jonathan Lord
Advisor of Third Rock Ventures
Jonathan Lord currently serves as the Chair of the Board of Directors of Dexcom, as a Director at Stericycle, and serves on advisory boards for Serco PLC (UK), Anthelio Health and Third Rock Ventures. He has earned certificates in Governance and Audit from the Harvard Business School. A nationally recognized leader in innovations in health care, Lord became the University of Miami’s Chief Innovation Officer when he returned to his alma mater after three decades in healthcare leadership roles, in September 2011. In March 2012, Lord was named Chief Operating Officer of the Miller School of Medicine and UHealth-University of Miami Health System. He completed a financial turnaround of the Miller School. A board-certified forensic pathologist who began his medical career in the U.S. Navy and later served as Chief Operating Officer of the American Hospital Association and several biotech companies, Lord served as the CEO for Navigenics, Inc. following his tenure as the former Chief Innovation Officer and Senior Vice President of Humana. During his time at Humana, he created Humana’s Innovation Center, which combines research, technology and consumer experience to promote health and well-being. He also contributed to the field of predictive sciences by using advanced analytics to predict who will become ill in the future and how to prevent disease. Further cementing his ties to UM, he oversaw the creation of the UM/Humana Health Resources Center on the Miller School campus in 2006. Lord also serves or has served as a member of a number of prestigious boards and organizations, including the Centers for Disease Control and Prevention’s Advisory Committee to the Director; the National Advisory Council for Healthcare Research and Quality, which advises the U.S. Secretary of Health and Human Services; and the Joint Commission on Accreditation of Health Care Organizations. He was a member of the President’s Council at UM, an advisory group of some of the University’s most prominent alumni. His previous academic appointments include Dartmouth Medical School, George Washington University and the Eastern Virginia School of Medicine.
Follow Jonathan Lord:
About : Third Rock Ventures invests in transformational life science companies that show high growth potential
Stephen Burley
Scientific Advisor of Proteorex Therapeutics Inc.
Follow Stephen Burley:
About : Expanding horizons to find cures
Monte Stettin
Advisor of doc.ai
Follow Monte Stettin:
About : doc.ai is a digital health company designed for a new generation of medical research.
Christopher K. Zarins
Founder & Senior Advisor for Clinical Affairs of HeartFlow
Follow Christopher K. Zarins:
About HeartFlow: HeartFlow is a medical technology company that provides new methods of diagnosis and treatment of cardiovascular disease.
Adam Rizvi, MD
Founding Advisor of Biovirtua
Adam Rizvi is the Neurocritical Care Director at Carondelet.
Follow Adam Rizvi, MD:
About Biomarker Labs, Biovirtua, Carondelet Health Network, Sound Physicians: Biovirtua offers a platform that monitors changes to human movement.
Kathleen Lester
Advisory Board Member of Medal
Follow Kathleen Lester:
About : Extract, transport, translate, and share medical records faster.
Joseph Kim
Sr. Advisor, Digital Health Office, Translational Technology & Innovation of Eli Lilly
Follow Joseph Kim:
About Eli Lilly, Eli Lilly: Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
Kyla Driscoll
Senior Research Advisor of Eli Lilly
Kyla Driscoll is currently a Senior Research Advisor and Group Leader in the Oncology Research division at Eli Lilly. Kyla Driscoll joined Eli Lilly In 2008 and is based in the New York laboratories of Lilly where her current efforts are focused on immune oncology targets and combinations with mechanistic analysis of biological activity. Driscoll is responsible for oversight and development of Lilly’s TGFβ platform, various immune checkpoint antagonists, and myeloid immuno-biology. These programs include both small molecules and biologics, and have advanced to various phases of clinical development. Driscoll obtained her Ph.D. in 2007 in microbiology and immunology where she studied viral mechanisms of oncogenesis. Driscoll further completed postdoctoral training in cancer vaccine development prior to joining Lilly.
Follow Kyla Driscoll:
About : Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
Amy Meadows
Senior Advisor, Consumer Marketing of Eli Lilly
Amy Meadows, head of consumer marketing for Lilly USA’s oncology business, has spent nearly two decades cultivating the art and science of marketing as an agency creative, an entrepreneur and, now, a client, most recently in healthcare. Recognised as a “gladiator for change” and one of Lilly’s Top 100 Innovators, Amy finds spirited purpose in empowering the voices of people who need to be heard – from those living with Alzheimer’s disease to those suffering from advanced/Stage IV cancer. She maximises her creativity outside of work through being an avid writer, artist, would-be Muppeteer and wrangler of five “tweenage” boys.
Follow Amy Meadows:
About : Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
David Kahn
Associate Engineering Advisor of Eli Lilly
Follow David Kahn:
About : Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
Michael Flanagan
Advisor, Radiation Technical of Sterigenics
Michael Flanagan is a Radiation Technical Advisor at Sterigenics.
Follow Michael Flanagan:
About Sterigenics: Sterigenics is a provider of solutions in sterilization and ionization supply chain management; Providing sterilization services.
Teo Forcht Dagi
Advisor of Broadview Ventures
T. (Teo) Forcht Dagi, M.D. is a Partner of HLM Venture Partners. Prior to joining HLM in 2006, Teo was a Managing Partner of Cordova Ventures in Atlanta and oversaw its life sciences and health care portfolio. Before joining Cordova Ventures, Teo served as Principal at Access Partners in Westport, CT. Prior to that, he taught and practiced neurosurgery on the faculties of Harvard, Brown and Georgetown Universities, the Uniformed Services University of the Health Sciences and the National Institutes of Health.
Follow Teo Forcht Dagi:
About : Broadview Ventures invests in businesses that focus on the development of technology solutions in cardiovascular and neurovascular diseases.
Serhat Pala
Chief Advisor of Confirm Biosciences
Serhat Pala is a serial entrepreneur who has co-founded, grown, and sold numerous businesses that have reached sizes up to $50M in annual revenue. The industries ranged from web application, SaaS and e-commerce in the early days of the Internet, and since the early 2000s focused on diagnostics, substance abuse, employee screening, and wellness. Serhat’s last company, Confirm BioSciences Inc is a diagnostic commercialization company that became one of the largest retail diagnostic providers in the nation, with products selling in over 25,000 retail locations (including Walmart, CVS, Walgreens, & Rite Aid). Throughout his tenure there, Confirm BioSciences also won numerous awards both locally and nationally, including Best Place to Work, CEO of the Year, Commercial Leadership Award, and others. Confirm BioSciences was recently acquired by one of the largest lab providers in the country in 2020.
Follow Serhat Pala:
About : The company manufactures and distributes instant diagnostic tests including urine tests, fertility tests and health tests.
Willard Dere
Scientific Advisors of Hangzhou Just Biotherapeutics (Just China)
Professor of Medicine, Executive Director of Personalized Health, Co-Director, Center for Clinical and Translational Science at the University of Utah. Board Member of BioMalin Pharmaceutical, Ocera Therapeutics and Radius Health. Former VP of Eli Lilly. As SVP of Global Development at Amgen, he was responsible for the clinical development of Raloxifene and other drugs for cancer, inflammation and kidney diseases.MD, University of California, Davis.
Follow Willard Dere:
About : Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
Robert Berliner
Member of the Board of Advisors of VG Life Sciences
Robert Berliner is the Of Counsel at Brooks Kushman P.C.
Follow Robert Berliner:
About Berliner & Associates, Brooks Kushman, Southern California Biomedical Council: VG Life Sciences discovers and develops drug therapies for cancers, infectious diseases, inflammatory diseases, and autoimmune disorders.
Russ Hensel
Member of the Board of Animal Toxicity Study Advisors of VG Life Sciences
Russ Hensel provides over 30 years of experience with Rhone-Poulenc Rorer, Covance Laboratories, Johnson & Johnson, and Tandem Labs. He designs and assesses pharmacokinetic data produced by our third party animal toxicity group. He received his PhD in Analytical Chemistry from Drexel University.
Follow Russ Hensel:
About : VG Life Sciences discovers and develops drug therapies for cancers, infectious diseases, inflammatory diseases, and autoimmune disorders.
Marshall Phelps
Member of the Board of Advisors of VG Life Sciences
Marshalll Phelps was appointed to Inventergy, Inc.’s Board of Directors on May 17, 2013. Phelps is a leading figure in the field of intellectual property management and performance, pioneering many of its leading strategies, generating unprecedented results and heading IP business and related activities at IBM and Microsoft. As CEO and Board Member of Article One Partners, he is actively engaged in helping businesses and governments improve patent quality and improve the Patent System. Phelps served as Corporate Vice President at IBM in the 1990s, responsible for overseeing standards, telecommunications policy, industry relations, licensing, intellectual property law and management of a worldwide intellectual property portfolio of more than 35,000 patents and 8,500 trademarks. By actively licensing these and other IP rights, such as trade secrets and copyrights, he transformed a function that had previously been costly overhead to a $2 Billion annual profit center. Prior to heading IP business, he served IBM as Director of Government Relations in Washington and as Vice President of Asia Pacific operations in Tokyo. From 2002-2010 Phelps served as Corporate Vice President and Deputy General Counsel for Intellectual Property and Licensing, Microsoft Corporation. At Microsoft, his duties entailed worldwide management of the company’s intellectual property portfolio, patent prosecution, licensing, standards and business development. He facilitated Microsoft’s emergence as one of the world’s largest IP companies with over 60,000 patents and applications, extensive copyright holdings and numerous trademarks. In 2006, Phelps was elected to the initial class of the Intellectual Property Hall of Fame. In 2001 he was founding partner with Nathan Myhrvold of Intellectual Ventures, now the largest acquirer of patents worldwide. His book, “Burning the Ships”, Intellectual Property and the Transformation of Microsoft, was published in 2009. Phelps has taught IP strategy at business, law or engineering schools at Duke, Cornell, UNC, and Berkeley and in Japan. He holds a B.A. and D.H.L from Muskingum University, an M.S. from Stanford Graduate School of Business, and a J.D. from Cornell University Law School.
Follow Marshall Phelps:
About : VG Life Sciences discovers and develops drug therapies for cancers, infectious diseases, inflammatory diseases, and autoimmune disorders.
Matthew Schiltz
Advisory Board Member and Investor of Parachute Health
Matthew Schiltz is the Advisory Board Member and Investor of Parachute Health.
Follow Matthew Schiltz:
About Parachute Health: Parachute Health is a provider of medical equipment ordering software.
Partha Mitra
Founder & Chief Scientific Advisor of Clarapath
Partha Mitra is the Professor at Cold Spring Harbor Laboratory.
Follow Partha Mitra:
About Clarapath, Cold Spring Harbor Laboratory, Indian Institute of Technology Madras: We are a medical robotics company developing the SectionStar, a platform to mimic the human histotechnician.
Reay Brown
Scientific Advisory Board of Ivantis
Dr. Reay H. Brown is a board certified ophthalmologist specializing in glaucoma, glaucoma surgery, and cataract surgery with intraocular lens implantation. He has been in practice in Atlanta since 1988. Dr. Brown earned his undergraduate degree from Harvard College Cum Laude and completed medical school at the University of Michigan. His training in ophthalmology was at the Wilmer Eye Institute of Johns Hopkins University. He then completed a glaucoma fellowship at the Bascom Palmer Eye Institute and returned to Johns Hopkins as Chief Resident and a member of the Hopkins faculty. Dr. Brown was selected as the first Pamela Firman Professor of Ophthalmology at the Emory Eye Center. Mrs. Firman made the donation for the professorship in gratitude for Dr. Brown’s care of her eyes. He served as the Director of the Glaucoma Service at Emory for eleven years prior to entering private practice with Atlanta Ophthalmology Associates in 1999. Dr. Brown has published more than 80 peer-reviewed articles on glaucoma, cataract surgery, and other aspects of eye care and is often asked to lecture on glaucoma at national and international meetings. He has received the Honor Award and the Senior Achievement Award from the American Academy of Ophthalmology. Dr. Brown is one of only a few ophthalmologists in Georgia who have received this prestigious award. Dr. Brown has been awarded 15 patents for new instruments to improve glaucoma and cataract surgery and has other patents pending. He continues to work on novel and improved approaches to glaucoma and cataract surgery. Dr. Brown has been selected by his peers to be listed each year in Best Doctors in America and was featured in a separate peer survey in Atlanta Magazine as one of the best ophthalmologists in Atlanta. Numerous media outlets, both local and national, have called attention to Dr. Brown’s contributions to cutting edge treatments in eye surgery.
Follow Reay Brown:
About Sight Sciences: Ivantis is focused on developing an innovative treatment for glaucoma which includes eye drops, laser therapy, and surgery.
Allan Geliebter
Clinical Advisor of Gelesis
Senior Attending Psychologist, St. Luke’s-Roosevelt Hospital; Pioneer in the gastric balloon field. Dr. Geliebter is Professor of Psychology at Touro College, Member of the New York Obesity Nutrition Research Center at St Luke’s-Roosevelt Hospital, as well as Senior Research Scientist in the Department of Psychiatry at Columbia University. Dr. Geliebter’s research interests include biological and psychological aspects of Binge Eating Disorder and the Night Eating Syndrome in overweight and obese individuals, brain imaging and binge eating, brain imaging pre and post obesity surgery, brain imaging and stress induced eating, genetics of obesity and neuroimaging, and environmental approaches for obesity intervention, including price discounts on healthy foods. He has a number of NIH grants to explore these topics. Dr. Geliebter received his Ph.D. from Columbia University.
Follow Allan Geliebter:
About : Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Lee M. Kaplan
Clinical Advisor of Gelesis
Dr. Lee Kaplan is the Director of the Obesity, Metabolism & Nutrition Institute, founding director of the Weight Center at the Massachusetts General Hospital, and Associate Professor of Medicine at Harvard Medical School. Dr. Kaplan’s clinical expertise is in the areas of obesity medicine, gastroenterology, and liver disease. He has a special interest in the causes and complications of obesity and the development of new and more effective preventive strategies and therapies for this problem. Dr. Kaplan serves as Chair of the Nutrition and Obesity Section of the AGA, Chair-elect of the Bariatric Surgery section of The Obesity Society, director of the Blackburn Obesity Course at Harvard Medical School, and Co-Chair of the Dartmouth Device Development Conference in Obesity and Metabolism. He is a member of the NIH Clinical Obesity Research Panel, was Chair of the recent FDA workshop on Device Development for Obesity and Metabolic Diseases, and is a member of the Obesity Medicine Certification Steering Committee. Dr. Kaplan graduated from Harvard University and received his M.D. and Ph.D. in molecular biology from the Albert Einstein College of Medicine. He completed an internship and residency in internal medicine and a fellowship in gastroenterology at Massachusetts General Hospital and Harvard Medical School, and a fellowship in genetics at Brigham and Women’s Hospital.
Follow Lee M. Kaplan:
About : Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Colin R. Gardner
Scientific Advisors of Kala Pharmaceuticals
Dr. Gardner was born and educated in Scotland, receiving a BSc and Ph.D. in chemistry from the University of Glasgow. After post-doctoral studies at Harvard Medical School (Biophysics) and MIT (Chemical Engineering), he returned to Europe and spent 2 years in the chemistry department at the University of Aberdeen followed by 6 years in drug discovery at the Merrell International Research Center in Strasbourg. Thereafter he joined Merck and Co. in the US, spending the first 4 years as a leader in a drug delivery group. He was then appointed to develop and lead a more effective interface between drug discovery and early pharmaceutical development; he pioneered the paradigm of early intervention which has become the standard in the industry. He progressed in the department to become VP and Global Head of formulation design and development for all Merck products – he was involved in the development of 16 small molecule NCEs whose combined maximum annual sales averaged $20Bn and three major vaccines. In 2001, Colin took early retirement from Merck to become the CSO of a start-up formulation company (TransForm Pharmaceuticals) in the Boston area. Four years later TransForm was acquired by Johnson & Johnson and led to major changes in the way in which J&J integrated discovery and early development. Colin stayed on as the President and Site Leader of TransForm. Colin retired from TransForm/J&J in June 2009 and is now an industry consultant.
Follow Colin R. Gardner:
About Lyndra Therapeutics: Kala Pharmaceuticals develops novel treatments for diseases that affect mucosal tissues.
Howie Rosen
Scientific Advisors of Kala Pharmaceuticals
Howie is an independent consultant and serves on the board of directors of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), CNS Therapeutics, Inc., PaxVax, Inc. and Pearl Therapeutics, Inc., where he served as interim President and CEO from June 2010 to March 2011. From 2004 to 2008, he was Vice President, Commercial Strategy at Gilead Sciences, Inc. where his responsibilities included strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead’s overall portfolio and business planning. Prior to joining Gilead, Mr. Rosen was President of ALZA Corporation where he was responsible for all aspects of managing ALZA as an independent 1000-person operating company within the Johnson & Johnson Family of Companies. Previously at ALZA as Vice President, Product Development, he was responsible for product development activities, portfolio management and corporate and new product planning. Over his 10 years at ALZA, Mr. Rosen also had responsibilities for mergers and acquisitions, R&D planning, and technology ventures. Prior to joining ALZA, Mr. Rosen managed the west coast practice of Integral, Inc., was Director, Corporate Development at GenPharm International, Inc. and was a consultant in the San Francisco office of McKinsey & Co. Mr. Rosen is a member of the Stanford University Advisory Council on Interdisciplinary Biosciences and was a member of the Stanford School of Engineering Advisory Council from 2004 to 2007. Mr. Rosen is also a member of the Biomedical Engineering Advisory Board at City College of New York and the BOD of the MIT Club of Northern California. Previously he was a member of the BODs of CoTherix, Inc and Pharsight Corporation. Mr. Rosen is a lecturer in the Department of Chemical Engineering at Stanford and teaches entrepreneurship at the Stanford Graduate School of Business. He is also a member of the National Academy of Engineering and co-inventor on 7 US patents. Mr. Rosen received an MBA from the Stanford Graduate School of Business, where he graduated first in his class as the Henry Ford II Scholar. Mr. Rosen has an MS in Chemical Engineering from MIT and he graduated with distinction from Stanford University with a BS in Chemical Engineering.
Follow Howie Rosen:
About Stanford Graduate School of Business: Kala Pharmaceuticals develops novel treatments for diseases that affect mucosal tissues.
Atul Butte
Co-Founder & Scientific Advisor of NuMedii
Atul Butte, MD, PhD is the Priscilla Chan and Mark Zuckerberg Distinguished Professor and inaugural Director of the Bakar Computational Health Sciences Institute (bchsi.ucsf.edu) at the University of California, San Francisco (UCSF). Dr. Butte is also the Chief Data Scientist for the entire University of California Health System, the tenth largest by revenue in the United States, with 20 health professional schools, 6 medical schools, 6 academic health centers, 10 hospitals, and over 1000 care delivery sites. Dr. Butte has been continually funded by NIH for 20 years, is an inventor on 24 patents, and has authored over 200 publications, with research repeatedly featured in the New York Times, Wall Street Journal, and Wired Magazine. Dr. Butte was elected into the National Academy of Medicine in 2015, and in 2013, he was recognized by the Obama Administration as a White House Champion of Change in Open Science for promoting science through publicly available data. Dr. Butte is also a founder of three investor-backed data-driven companies: Personalis (IPO, 2019), providing medical genome sequencing services, Carmenta (acquired by Progenity, 2015), discovering diagnostics for pregnancy complications, and NuMedii, finding new uses for drugs through open molecular data. Dr. Butte trained in Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, trained in Pediatrics and Pediatric Endocrinology at Children’s Hospital Boston, then received his PhD from Harvard Medical School and MIT.
Follow Atul Butte:
About NuMedii, Personalis, University of California, San Francisco: NuMedii is a biotechnology company that discovers and de-risks effective drugs by translating life sciences big data into therapies.
Luciano Marraffini
Founder & Advisor of Intellia Therapeutics
Luciano Marraffini is an Assistant Professor of Bacteriology at Rockefeller University. Luciano’s laboratory investigates the underlying molecular mechanisms of CRISPR immunity, and seeks to employ this natural pathway to develop new technologies. He is a 2012 Rita Allen Foundation Scholar and the recipient of a 2012 NIH Director’s New Innovator Award. Luciano received his PhD from the University of Chicago where he studied bacterial pathogenesis, and completed his postdoctoral fellowship at Northwestern University.
Follow Luciano Marraffini:
About Eligo Bioscience, Intellia Therapeutics, The Rockefeller University: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Don Kasle
Advisor of Carepoynt
Don Kasle is the Tech Coast Angels’ Chairman Emeritus, the largest Angel Investment Network in the USA and Senior Consultant at TriTech, Small Business Development Center. Don, a retired bank CEO, is Managing Partner of Alldas Partners, a financial services consulting company. He has over 40 years’ experience in executive management and service on boards of directors, as well as commercial banking and capital formation. Mr. Kasle is also an active investor in and a coach for start-up companies through his membership in the Tech Coast Angels where he also serves on the Board of Governors as well as a member of the executive committee for the Orange County Network. During his career, Mr. Kasle has served on over 30 Boards of Directors in the public, private and not-for profit sectors, including 7 bank boards.
Follow Don Kasle:
About : Carepoynt is the first Rewardsware for Healthcare program, platform and network for patients, providers, employers, payers and partners
Deep Nishar
Member, Board of Advisors of MUrgency
Follow Deep Nishar:
About : MUrgency Inc. is a holding company for multiple businesses playing the role of the idea generator, incubator, accelerator& growth hacker
Jim Young
Lead Tech Advisor of MUrgency
Follow Jim Young:
About MUrgency: MUrgency Inc. is a holding company for multiple businesses playing the role of the idea generator, incubator, accelerator& growth hacker
Jim Young
Lead Tech Advisor of MUrgency
Follow Jim Young:
About MUrgency: MUrgency Inc. is a holding company for multiple businesses playing the role of the idea generator, incubator, accelerator& growth hacker
William A Sanger
Member, Board of Advisors of MUrgency
Follow William A Sanger:
About : MUrgency Inc. is a holding company for multiple businesses playing the role of the idea generator, incubator, accelerator& growth hacker
Rex Teeslink
Co-founder, Inventor & Scientific Advisor of Advanced Catheter Therapies
Rex Teeslink, M.D. is a vascular and interventional radiologist with over 40 years of experience. He received his M.D. degree from Tulane University School of Medicine in New Orleans and completed his radiology residency at the University of Virginia in Charlottesville. Dr. Teeslink began his practice in 1968 as Chief of Vascular and Interventional Radiology at the Medical College of Georgia, the Veterans Administration and three private hospitals in Augusta, Georgia. He served in this capacity for 30 years, and continues his medical practice through medical consulting companies. Dr. Teeslink has been actively involved throughout his career in leading-edge technology and continues to assist in the design, development and implementation of numerous medical devices and X-ray equipment. Dr. Teeslink has served as medical director and consultant for several companies. He has been instrumental in helping develop many of the interventional procedures that are utilized today. Dr. Teeslink has always been involved in medical education endeavors, including training medical students, residents, fellows and post graduate physicians. A recognized expert in his field, he has shared his knowledge and experience at numerous medical conferences, both nationally and internationally.
Follow Rex Teeslink:
About Advanced Catheter Therapies: Advanced Catheter Therapies develops catheter technologies targeting vascular disease including thrombosis, inflammation, and occlusions.
Larry Melvin
Member of the Scientific Advisory Board of AI Therapeutics
Larry Melvin is Member of the Scientific Advisory Board at LAM Therapeutics.
Follow Larry Melvin:
About : AI Therapeutics develops drugs for rare diseases and cancer.
Robert Weinberg
Advisory Board Member of Rafael Pharmaceuticals
Robert Weinberg is a pioneer in cancer research who is most widely known for his discoveries of the first human oncogene—a gene that causes normal cells to form tumors—and the first tumor suppressor gene. Weinberg, who received his PhD in biology from Massachusetts Institute of Technology in 1969, has held research positions at the Weizmann Institute and the Salk Institute. In 1982, Weinberg helped found Whitehead Institute, joined the faculty as a professor of biology at MIT, and published his landmark paper Mechanism of Activation of a Human Oncogene in the journal Nature. In 1999, another major paper, Creation of Human Tumor Cells with Defined Genetic Elements, was also published in Nature. Weinberg’s awards include Scientist of the Year by Discover magazine (1982), Bristol-Myers Award for Distinguished Achievement in Cancer Research (1984), Member of the U.S. National Academy of Sciences, National Medal of Science (1997), Wolf Prize in Medicine (2004), Landon-AACR Prize for Cancer Research (2006), Otto Warburg Medal (2007). Weinberg serves on the Scientific Advisory Boards of Novartis and Motorola, among others.
Follow Robert Weinberg:
About : Rafael Pharmaceuticals is clinical-stage, metabolic oncology therapeutics company.
Luigi Xerri, PhD
Founder, Senior Strategic Advisor and Head of Scientific Affairs of Venatorx Pharmaceuticals
Dr. Xerri is Founder, Senior Strategic Advisor and Head of Scientific Affairs at VenatoRx Pharmaceuticals. He was co-founder and Chief Scientific Officer of Protez Pharmaceuticals and was previously Director of Antimicrobial Disease Strategy at GlaxoSmithKline. He had responsibility for the appropriate risk assessment of the portfolio, aligning discovery with Business Development, and to fill gaps via in-licensing. During his 36 year career in antibacterials, he has led or been part of international teams for the pre-clinical and clinical development of cephalosporins (cefuroxime and ceftazidime), carbapenems (Sanfetrinem and Razupenem) and quinolones (ofloxacin, levofloxacin and grepafloxacin) and made key contributions to their commercialization strategies. Dr. Xerri holds a Laurea in Biology and Microbiology from the University of Bologna, Italy.
Follow Luigi Xerri, PhD:
About Venatorx Pharmaceuticals: Venatorx Pharmaceuticals develops a novel anti-infectives to treat multi-drug-resistant bacterial infections and viral infections.
James Farinholt
Senior Financial Advisor, Treasurer & Board of Directors of PluroGen Therapeutics
Mr. Farinholt has had an extensive career in both the private and public sectors of finance and investment. Since 1992, he has been engaged in business development at Virginia Commonwealth University as Special Assistant for Economic Development to the President. During his promotion of commercialization of scientific discoveries at the University, he co-founded Allos Therapeutics, Inc. (NASDAQ: ALTH) a pharmaceutical start-up, which went public in March 2000. In 1994 and 1995, Mr. Farinholt was Interim Director of Technology Transfer at VCU and continues to serve on the Board of Directors of the Intellectual Properties Foundation of which he was a founding member. From 1996 through 1998, he was Executive Director of the Virginia Biotechnology Research Park Authority where he oversaw the development of the initial 257,000 square feet of office and laboratory facilities. Prior to joining VCU, Mr. Farinholt had thirty years of experience in investment banking for small and medium-sized businesses as an executive officer at The Chase Bank in New York, in Wheat First Union and Galleher & Company in Richmond, Virginia. He is a partner at Whetstone Partners, LLC and Tall Oaks Capital. Among Mr. Farinholt’s directorships are: PharmaNetics, Inc. (NASDAQ: PHAR), BioCache Pharmaceuticals, Inc., a privately owned bio-tech start-up and Owens & Minor, Inc. (NYSE: OMI), the nation’s leading distributor of name-brand medical/surgical supplies, with annual revenues in excess of $4 billion, where he is Chairman of the Audit Committee and a member of the Executive and Strategic Planning Committees.
Follow James Farinholt:
About Tall Oaks Capital Partners, Virginia BioTechnology Research Park, Whetstone Partners: PluroGen Therapeutics provides clinically advanced and advantaged burn, wound, and skin care products.
Daniel Levner
Co-Founder & Chairman of the Scientific Advisory Board of Sight Diagnostics
Daniel Levner is Emulate’s Chief Technology Officer. Prior to joining Emulate’s founding team, he was a Senior Staff Scientist with the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he led the advanced engineering team responsible for developing Emulate’s Organs-on-Chips platform. Levner played a key leadership role in managing the multidisciplinary Organs-on-Chips team by formulating innovative approaches for fostering close collaboration and in-depth exchange between biologists and engineers. Levner brings this tight integration of disciplines to Emulate, where it is a defining part of the company’s culture. Prior to directing the Organs-on-Chips program, Levner worked with world-renowned Harvard geneticist Prof. George M. Church in programs related to medical diagnostics, DNA/RNA sequencing tools, and multiplexed analysis techniques. As an entrepreneur, Levner co-founded a medical diagnostics startup company, and earlier in his career, an optical telecommunications startup company. Levner received his Ph.D. in electrical engineering from Stanford University as well as an M.S. in aeronautics and astronautics, also from Stanford. He has authored numerous publications and more than 20 issued and pending patents.
Follow Daniel Levner:
About Emulate, Sight Diagnostics: Blood diagnostics company that uses machine vision and AI to transform health systems and outcomes through fast and accurate blood testing.
Dehua Pei
Co-Founder and Chief Scientific Advisor of Entrada Therapeutics
Follow Dehua Pei:
About Entrada Therapeutics: Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Donna D’Amico
Board of Advisors of WellTrackONE
Donna D’Amico is Board of Advisors at WellTrackOne.
Follow Donna D’Amico:
About : WellTrackONE provides patient health and wellness programs to healthcare providers and organizations.
Dave Bronkart
Patient Perspectives Advisor of Antidote.me
Diagnosed in 2007 with advanced kidney cancer, e-Patient Dave deBronkart rapidly learned to use every aspect of empowerment, technology, and participatory medicine to beat the odds. A founding co-chair of the Society for Participatory Medicine, in 2009 he became an international spokesman for the e-patient movement, and in 2010 left his previous career to work full time in transforming healthcare.
Follow Dave Bronkart:
About : Antidote is a digital health company that accelerates and improves medical research by combining technologies, data, and business models.
Sanjiv Gambhir
Board Advisor of RefleXion Medical
Dr. Sanjiv Sam Gambhir is the Virginia and D.K. Ludwig Professor of Cancer Research and the Chair of Radiology at Stanford University School of Medicine. He also heads up the Canary Center at Stanford for Cancer Early Detection. He received his MD/PhD from the UCLA Medical Scientist Training Program. He has over 400 publications in the field and over 40 patents pending or granted. An internationally recognized researcher in molecular imaging with over $75 Million of NIH funding as the PI, his lab has focused on interrogating fundamental molecular events in living subjects. He has developed and clinically translated several multimodality molecular imaging strategies including imaging of gene and cell therapies. He has also developed strategies for Raman and Photoacoustic molecular imaging. He serves as an advisor to several companies including General Electric Medical Systems and Bayer-Schering and has also co-founded several imaging startups. He serves on numerous academic advisory boards for Universities around the world and is also a member of the Scientific Advisory Board of the National Cancer Institute. Among his many awards he is the recipient of the George Von Hevesy Prize and the Paul C. Aebersold Award for outstanding achievement in basic nuclear medicine science from the Society of Nuclear Medicine, Outstanding Researcher Award from the Radiological Society of Northern America in 2009, the Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation, the Holst Medal, the Tesla Medal, and the Hounsfield Medal from Imperial College, London. He was also elected to the Institute of Medicine of the US National Academies in 2008.
Follow Sanjiv Gambhir:
About National Institutes of Health, Stanford University School of Medicine: RefleXion Medical is a developer of biologically-guided radiotherapy systems for patients with cancer.
Douglas J. Jolly
Founder, Chief Advisor of Abintus Bio
Douglas J. Jolly is the Co-Founder, Chief Advisor at Abintus Bio, Inc.
Follow Douglas J. Jolly:
About Abintus Bio: Abintus Bio engages in the field of in vivo immune cell reprogramming.
Warren Zapol
Chairman of the Board of Advisor of Third Pole
Warren Zapol was a co-inventor on our key patents from MGH, and is a co-inventor of inhaled Nitric Oxide, for which he received the 2003 Inventor of the Year award from the Intellectual Property Owners Association.
Follow Warren Zapol:
About : Third Pole develops products that generate and deliver electric nitric oxide for hospital, ambulatory, and home use.
Evan Edwards
Key Strategic Advisor of kaleo
Evan Edwards is the Key Strategic Advisor at Kaléo.
Follow Evan Edwards:
About AAMI, Kymanox: kaleo is a pharmaceutical company that develops combination drug products that empowers patients to control their medical conditions.
James McClung
Advisory Board Member of 4D Healthware
Follow James McClung:
About : 4D Healthware is patient engagement software that makes personalized medicine possible through connected data.
James McClung
Advisory Board Member of 4D Healthware
Follow James McClung:
About : 4D Healthware is patient engagement software that makes personalized medicine possible through connected data.
Roy Herbst
Member of Scientific Advisory Board of Kolltan Pharmaceuticals
Roy Herbst is Member of Scientific Advisory Board at Kolltan Pharmaceuticals.
Follow Roy Herbst:
About : Kolltan Pharmaceuticals develops new-generation monoclonal antibody oncology therapeutics.
Sachdev Sidhu
Member of Scientific Advisory Board of Kolltan Pharmaceuticals
Sachdev Sidhu is Member of Scientific Advisory Board at Kolltan Pharmaceuticals.
Follow Sachdev Sidhu:
About : Kolltan Pharmaceuticals develops new-generation monoclonal antibody oncology therapeutics.
Sachdev Sidhu
Member of Scientific Advisory Board of Kolltan Pharmaceuticals
Sachdev Sidhu is Member of Scientific Advisory Board at Kolltan Pharmaceuticals.
Follow Sachdev Sidhu:
About : Kolltan Pharmaceuticals develops new-generation monoclonal antibody oncology therapeutics.
Mark Lemmon
Member of Scientific Advisory Board of Kolltan Pharmaceuticals
Mark Lemmon is Member of Scientific Advisory Board at Kolltan Pharmaceuticals.
Follow Mark Lemmon:
About : Kolltan Pharmaceuticals develops new-generation monoclonal antibody oncology therapeutics.
Mark Coreil
Advisor of Oral4D Systems
Dr. Mark Coreil is a Board Certified Orthodontist and an Assistant Professor of Clinical Orthodontics at the Louisiana State University School of Dentistry. For the past 10 years he has been actively involved as an Orthodontist on the Children’s Hospital Cleft and Craniofacial Team. He lectures internationally and nationally on orthodontic treatment and practice operational topics and cares for his patients at Le Centre Orthodontic Arts in Houma, Louisiana. Dr. Coreil is a lead user of Oral4D Ortho and he and his practice staff provide invaluable input on solution benefits and workflow.
Follow Mark Coreil:
About : Oral4D uses visual communications to solve problems caused by lack of standardization, accuracy and analytics in text-based health records.
Robert O’Holla
Senior Advisor – Medtech of Endeavour Vision
Follow Robert O’Holla:
About CeQur, Endeavour Vision: Endeavour Vision is a growth-stage investor that invests in growth-stage medtech and digital health companies in Europe and the US.
Robert Fisher
Co-Founder & Chief Medical Advisor of Avails Medical
Dr. Fisher is Maslah Saul MD Professor and Director of the Stanford Epilepsy Center. He had research awards from the Klingenstein Foundation, EF, CURE and NIH. He published 160 peer-reviewed articles and 5 books. He was named 1996-2013 in Best Doctors in America. He received the Ambassador Award from the International League Against Epilepsy, the 2005 AES Service Award and the 2006 Annual Clinical Research Award. Dr. Fisher is Past-President of the American Epilepsy Society, and has served on the Board of the ILAE and as Editor-in-Chief of the Journal, Epilepsia. He is past Editor-in-Chief of the website epilepsy.com. His research is on new devices to treat epilepsy.
Follow Robert Fisher:
About Avails Medical: Avails Medical has developed digital technology to provide accurate, rapid detection of infections.
Jonathan Heusal
Member of the Board of Advisors of PierianDx
Heusel completed his graduate immunology, medical, laboratory medicine residency and research fellowship training at Washington University School of Medicine. He was on faculty at the University of Iowa, Department of Pathology for 11 years, where he helped to build clinical Molecular Pathology services and training programs. He is certified by the American Board of Pathology in the specialties of Clinical Pathology and Molecular Genetic Pathology. He has expertise in molecular diagnostic assay development across various platforms including next-generation sequencing, laboratory administration and compliance, and the biomedical areas of molecular and cellular immunology, and virology. His primary interest is to accelerate the translation of biomedical discoveries into effective healthcare solutions using robust technology and sound laboratory science.
Follow Jonathan Heusal:
About : PierianDx is catalyzing global adoption of genomic sequencing in healthcare
Allie Grossmann
Member of the Board of Advisors of PierianDx
Grossmann received a BS in zoology at the College of Idaho and a PhD and MD from the Oregon Health Sciences University, where she studied tyrosine kinase substrate specificity with Brian J. Druker, MD. Grossmann completed both a residency in anatomic pathology and a research fellowship in molecular medicine at the University of Utah. Her postdoctoral work in the laboratory of Dean Y. Li, MD, PhD, focused on the role of small GTPases in melanoma invasion and metastasis. Most recently, Grossmann completed a fellowship in molecular genetic pathology at ARUP Laboratories. Her primary subspecialty interests are sarcoma pathology and molecular oncology. Her research interests include mechanisms of tumorgenesis, metastasis, and the development of targeted therapies for cancer treatment.
Follow Allie Grossmann:
About : PierianDx is catalyzing global adoption of genomic sequencing in healthcare
David Baltimore
Member of the Medical Advisory Board of The Howard Hughes Medical Institute
David Baltimore is President Emeritus and Robert Andrews Millikan Professor of Biology at the California Institute of Technology, or Caltech.
Follow David Baltimore:
About Appia Bio, Calimmune, Caltech, Caltech, The Column Group: The Howard Hughes Medical Institute, a non-profit medical research organization, aims to advance biomedical research and science education.
Peter Mundel
Co-Founder & Executive Scientific Advisor of Goldfinch Biopharma
Peter Mundel is the Entrepreneur-in-Residence at Atlas Venture.
Follow Peter Mundel:
About Atlas Venture, Goldfinch Biopharma: Goldfinch is a clinical-stage biotech company focused on discovering and developing precision therapies for patients with kidney disease.
Patrick J. McGinnis
Advisory Board of Houston Health Ventures
HHV Advisory Board, Director of Medical Informatics, Memorial Hermann-Texas Medical Center Adjunct Professor, UT Houston School of Biomedical Informatics
Follow Patrick J. McGinnis:
About Houston Health Ventures: HHV is a seed-stage healthcare investment fund focused on health IT.
Kan Au
Clinical Advisor of Strados Labs
Follow Kan Au:
About Strados Labs: Strados Labs innovates respiratory monitoring using smart biosensors and artificial intelligence.
Charles S. Craik
Co-Founder and Chairman of Scientific Advisory Board of Catalyst Biosciences
Charles S. Craik, Ph.D. is a Professor in the Departments of Pharmaceutical Chemistry, Cellular & Molecular Pharmacology, and Biochemistry & Biophysics at the University of California at San Francisco (UCSF) and also the Director of the Chemistry and Chemical Biology Graduate Program. Dr. Craik co-founded Catalyst Biosciences, Inc., in 2003 and served as its Chairman of the Board and President. He serves as Chairman of Scientific Advisory Board of Catalyst Biosciences, Inc. He served as Chairman and Member of Advisory Board of Catalyst Biosciences, Inc. He serves as Scientific Advisor of Ironwood Pharmaceuticals Inc. (a/k/a Microbia, Inc.). He joined the UCSF faculty in 1985. He serves on advisory panels for the National Institutes of Health, the National Science Foundation, the National Academy of Sciences and the Department of Energy. Dr. Craik is Associate Editor of the Journal Protein Engineering and has co-authored two books. He has organized several international meetings on topics including Protein Engineering, Drug Discovery, and The Biology of Proteolysis. He has published over 200 research articles on various biochemical topics. He focuses on the Chemical Biology of proteolytic enzymes and their natural inhibitors. He serves as Member of Scientific Advisory Board at Protagonist Pty Ltd. Dr. Craik received his Ph.D. in Chemistry from Columbia University in New York and carried out his postdoctoral research at UCSF with Dr. William Rutter.
Follow Charles S. Craik:
About Catalyst Biosciences: Catalyst Biosciences is a drug R&D company creating catalytic biopharmaceutical products based on engineered human proteases.
Craig Coombs
Regulatory Advisor of Magnetic Insight
Follow Craig Coombs:
About : MPI enables best in class cellular imaging to measure the efficacy of cancer immunotherapies.
David Panzarella
Commercial Advisor of Magnetic Insight
Follow David Panzarella:
About Magnetic Insight: MPI enables best in class cellular imaging to measure the efficacy of cancer immunotherapies.
Max Wintermark
Medical Advisor of Magnetic Insight
Follow Max Wintermark:
About : MPI enables best in class cellular imaging to measure the efficacy of cancer immunotherapies.
Cindy Domecus
Chief Regulatory Advisor of Alydia Health
Cindy Domecus currently works as Chief Regulatory Advisor at Alydia Health.
Follow Cindy Domecus:
About Alydia Health: Alydia Health is a medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage.
George Daniloff
Advisor of AdminMed
Follow George Daniloff:
About : AdminPen™ device is a painless user-friendly inexpensive needle substitute based on the patented proprietary microneedle array.
Deepak Srivastava
Co-Founder and Co-Chair of The Scientific Advisory Board of iPierian
Dr. Deepak Srivastava, M.D., is the Scientific Co-Founder and Co-Chair of The Scientific Advisory Board at iPierian, Inc. He serves as Director of the Gladstone Institute of Cardiovascular Disease, a professor of the departments of Pediatrics and Biochemistry and Biophysics, and Wilma and Adeline Pirag Distinguished Professor in Pediatric Developmental Cardiology at the University of San Francisco (UCSF).
Follow Deepak Srivastava:
About iPierian, Tenaya Therapeutics: iPierian is a drug discovery platform that develops therapies for neurodegenerative diseases such as SMA, ALS, and Parkinson’s.
Simon Choi
Senior Science Health Advisor of U.S. Food and Drug Administration
Simon Choi is a Office of Center Director at FDA.
Follow Simon Choi:
About U.S. Food and Drug Administration: U.S. Food and Drug Administration is a federal agency responsible for protecting and promoting public health.
Reginald Bell
Medical Advisory Board of EndoGastric Solutions
Reginald Bell is Medical Advisory Board at EndoGastric Solutions.
Follow Reginald Bell:
About : EGS manufactures EsophyX technology is used to reconstruct the gastroesophageal valve in the TIF 2.0 procedure.
Joseph Madsen
Clinical and Scientific Advisor Board of Alcyone Lifesciences
Dr. Madsen’s research interests focus on application of signal processing and biophysical modeling to understand such problems in pediatric neurosurgery as hydrocephalus and epilepsy. A major thrust is the integration of multiple levels of study and understanding of molecular, dynamic, functional, and clinical phenomena. Some projects culminate in device and therapeutical protocol design. Dr. Madsen received his BA in chemistry from the University of Utah in 1976 and his MD from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology in 1981. He completed his internship in surgery at the Beth Israel Hospital and his residency in neurosurgery at the Massachusetts General Hospital. Following his residency, Dr. Madsen completed an Elsberg Fellowship in Neurological Surgery and a Clinical Investigator Development Award (CIDA) fellowship. An epilepsy neurosurgeon, Dr. Madsen is known as an innovator in clinical as well as research realms. He organized the Laboratory of Neurodynamics in 2000 to combine clinical research with the opportunity to do truly basic research involving data from human subjects. This opportunity is uniquely available because the need and benefits of neurosurgical intervention, advanced technologies, such as digital signal processing (DSP), wavelet analysis, and cutting edge cognitive science combine in this new laboratory. Another exciting clinical issue involves the growing technology of electrostimulation (of the vagus nerve presently, other targets in the future) in the treatment of epilepsy. Quantitative approaches are employed to advance understanding of the mechanism of these new technologies, as well as the pioneering investigation of new methods. True to his HST roots, Madsen also applies mathematical modeling methods to the common pediatric neurosurgical problem of hydrocephalus. Research in his lab spans from “first-principles” modeling, to systems identification using real data, to analysis of transgenic animals along these lines from a mechanistic view. Other interests include control theory in a new generation of neurosurgical robots, simple technologies to avoid need for neurosurgical intervention, neurosurgery of the fetus, and the future of neurosurgical education.
Follow Joseph Madsen:
About : Alcyone Lifesciences develops a platform of technology that optimizes molecular therapy for the brain.
Jonathan Libov
Strategic Product Advisor of Figure 1
Jonathan Libov is Analyst at Union Square Ventures.
Follow Jonathan Libov:
About : Figure 1 connects healthcare professionals around the world to view, discuss, and share medical cases.
Robert Morin, MD, MBA, FACS
Consultant/Advisor of EpiBone
Robert J. Morin, MD, FACS is a board certified plastic surgeon who performs a full range of plastic surgery procedures. In addition to general plastic surgery, Dr. Morin specializes in reconstructive and cosmetic surgery of the head and face. Dr. Morin received extensive additional training in craniofacial surgery, facial cosmetic surgery and pediatric plastic surgery. This additional training allows him to successfully perform a wide range of complex reconstructive and cosmetic surgical procedures on both adults and children. Dr. Morin has a specific interest in nasal reconstruction, ear reconstruction and cosmetic and cleft rhinoplasty. Dr. Morin attended New York Medical College where he was a member of the Alpha Omega Alpha Honor Medical Society and also served as Vice President of the college chapter of the American Medical Association. After receiving his medical degree, Dr. Morin completed a combined general surgery and plastic surgery residency at the University of Medicine and Dentistry of New Jersey, during which time he served as Plastic Surgery Chief Resident. Continuing his post-graduate training, Dr. Morin pursued his special interest as a Craniofacial and Pediatric Plastic Surgery Fellow at Miami Children’s Hospital in Miami, Florida. During that time, Dr. Morin had the privilege of training with one of the world’s most respected craniofacial surgeons, Dr. S. Anthony Wolfe. Dr. Morin has researched extensively and has been published widely in the medical literature. He has presented his work at medical conferences from New York to Israel. Dr. Morin has also traveled extensively to underdeveloped countries in order to help children in need of complex surgical care. In the past several years, he has operated in Costa Rica, Mauritius, the Philippines and Colombia. In addition, Dr. Morin was one of the first plastic surgeons on the ground in Haiti, operating on children following the devastating earthquake in January 2010. He has received numerous Awards of Distinction in recognition of his services to the children of these foreign regions and was featured on the ABC Nightline special about the United States surgical effort in Haiti titled “ER: Haiti.” In the United States, Dr. Morin works closely with dermatologists, surgical oncologists, neurosurgeons, pediatricians and trauma surgeons in order to restore normal appearance and function to patients affected by congenital abnormalities, cancer and trauma. Dr. Morin believes that all “reconstructive” procedures are judged on their “aesthetic” result. Therefore, Dr. Morin’s goal is always to produce the best cosmetic result possible, regardless of whether he is repairing a cleft lip or performing a breast augmentation. Dr. Morin practices plastic surgery in New York City and New Jersey.
Follow Robert Morin, MD, MBA, FACS:
About : EpiBone is a bone reconstruction company that advances skeletal reconstruction through 3D design and living cells.
Jeff Yao
Advisor of DSP Concepts, Inc.
Follow Jeff Yao:
About : Silicon Valley based leader in the Audio of Things market and the creator of Audio Weaver, the platform that makes audio innovation easy
David Wang
Advisor to semiconductor sector of DSP Concepts, Inc.
Follow David Wang:
About : Silicon Valley based leader in the Audio of Things market and the creator of Audio Weaver, the platform that makes audio innovation easy
David H. Sachs
Scientific Advisor of Eliaz Therapetuics
Follow David H. Sachs:
About Columbia University, ITBMed, Pandion Therapeutics: Eliaz Therapeutics is developing a novel treatment using targeted therapeutic apheresis to remove Galetin-3 from the body
Jeffrey L. Winters
Scientific Advisor of Eliaz Therapetuics
Follow Jeffrey L. Winters:
About : Eliaz Therapeutics is developing a novel treatment using targeted therapeutic apheresis to remove Galetin-3 from the body
Jeffrey L. Winters
Scientific Advisor of Eliaz Therapetuics
Follow Jeffrey L. Winters:
About : Eliaz Therapeutics is developing a novel treatment using targeted therapeutic apheresis to remove Galetin-3 from the body
Patrick M. Moriarty
Scientific Advisor of Eliaz Therapetuics
Follow Patrick M. Moriarty:
About : Eliaz Therapeutics is developing a novel treatment using targeted therapeutic apheresis to remove Galetin-3 from the body
Glenn M. Chertow
Scientific Advisor of Eliaz Therapetuics
Follow Glenn M. Chertow:
About : Eliaz Therapeutics is developing a novel treatment using targeted therapeutic apheresis to remove Galetin-3 from the body
Osama E. Rahma
Founder, Chief Medical Advisor of Outcomes4Me
Osama Rahma is the Founder and Chief Medical Advisor of Outcomes4Me.
Follow Osama E. Rahma:
About Outcomes4Me: Outcomes4Me is a developer of a free mobile app and platform to navigate cancer treatment and care.
Thomas Kurk
Board of Advisor & Corporate Advisor of BrownIT Holdings
Follow Thomas Kurk:
About : BITH is an acquisition platform designed to quickly capture a share of the rapidly expanding Health IT market.
Olessia Smotrova- Taylor
Board of Advisor & Corporate Advisor of BrownIT Holdings
Follow Olessia Smotrova- Taylor:
About : BITH is an acquisition platform designed to quickly capture a share of the rapidly expanding Health IT market.
Rick Leimbach
Board of Advisor & Corporate Advisor of BrownIT Holdings
Follow Rick Leimbach:
About : BITH is an acquisition platform designed to quickly capture a share of the rapidly expanding Health IT market.
Clifford J. Hunt
Board of Advisor & Corporate Advisor of BrownIT Holdings
Follow Clifford J. Hunt:
About : BITH is an acquisition platform designed to quickly capture a share of the rapidly expanding Health IT market.
